NEU — Neuren Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$2.95bn
- AU$2.66bn
- AU$64.63m
Australia's Neuren Pharma at more than 2-month-low on revising royalty outlook
Brief: Neuren Pharmaceuticals Says Fast Track Granted By FDA For NNZ-2591 In Phelan-Mcdermid
Australia's Neuren Pharmaceuticals rises to 1-1/2-year high on FDA Fast Track designation
Brief: Neuren Pharmaceuticals Partners With Hope For Hie To Support Nnz-2591
Australia's Neuren Pharmaceuticals hits more than 1-year high on strong HY results
Australia's Neuren Pharmaceuticals hits one-year high on DAYBUE sales jump
Brief: Neuren Pharmaceuticals Says Daybue Q2 2025 Net Sales $96.1 Million
Australia's Neuren Pharmaceuticals jumps on drug patent approval in US
Australia's healthcare stocks drop as Trump plans executive order to cut prescription drug prices
Brief: Neuren Pharmaceuticals Says Daybue Q1 2025 Net Sales $84.6 Million
Australia's Neuren Pharmaceuticals rises on FDA trial update
Brief: Neuren Pharmaceuticals Receives First Daybue Sales Milestone Payment
Brief: Neuren Pharmaceuticals Gets Rare Pediatric Disease Designation From US FDA
Australia's Neuren Pharmaceuticals climbs to two-week high on US FDA designation
Australia's Neuren Pharma gains on US FDA 'fast track' tag for Pitt Hopkins drug
Brief: Neuren Pharmaceuticals Says Type C Meeting Granted By US FDA
Australia's Neuren Pharma hits over 3-month high on $32 mln share buyback
Brief: Neuren Pharmaceuticals Announces A$50M On-Market Share Buy-Back Program
Australia's Neuren Pharmaceuticals hits 1-month high on upbeat sales